Results 121 to 130 of about 19,437 (169)
Navigating chylous pericardial effusion: a case study and evidence-based review of management options. [PDF]
J Cardiothorac SurgPhey ZYD, Lizwan M, Chia CML.
europepmc +1 more source
Symptom management with osilodrostat in multiple endocrine neoplasia type 1 with a Cushing syndrome presentation. [PDF]
JCEM Case RepJamal HF.
europepmc +1 more source
Ectopic Olfactory Neuroblastoma of the Maxillary Sinus: A Case Report. [PDF]
Clin Case RepJahandideh H, Yadmehr F, Abrishami M.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Octreotide and Octreotide-derived delivery systems
Journal of Drug Targeting, 2023Pharmaceutical peptide Octreotide is a somatostatin analog with targeting and therapeutic abilities. Over the last decades, Octreotide has been developed and approved to treat acromegaly and neuroendocrine tumours, and Octreotide-based radioactive conjugates have been leveraged clinically to detect small neuroendocrine tumour sites.
Mingliang, Fan +4 more
openaire +2 more sources
Expert Review of Endocrinology & Metabolism, 2007
Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance.
R. Cozzi, R. Attanasio
openaire +2 more sources
Octreotide has dramatically changed the results of medical treatment of acromegaly. It is the reference drug for the pharmacological treatment of acromegaly, owing to its impressive efficacy in suppressing growth hormome secretion, and excellent compliance.
R. Cozzi, R. Attanasio
openaire +2 more sources
Annals of Pharmacotherapy, 1997
In a limited number of case reports in infants, octreotide raised the blood glucose concentrations and decreased glucose requirements sufficiently to avoid pancreatectomy. This response occurs in the presence of frequent feedings and diazoxide therapy, and lasts from 1 month to greater than 5 years.
openaire +2 more sources
In a limited number of case reports in infants, octreotide raised the blood glucose concentrations and decreased glucose requirements sufficiently to avoid pancreatectomy. This response occurs in the presence of frequent feedings and diazoxide therapy, and lasts from 1 month to greater than 5 years.
openaire +2 more sources